Key result
Prehospital IV furosemide is not associated with lower hospital mortality in acute heart failure.
Why the study?
The study aimed to evaluate the association between prehospital intravenous therapy and clinical outcomes in patients with acute heart failure.
Does prehospital intravenous furosemide or nitrates improve hospital mortality or length of stay in patients with acute heart failure?
Observational (n=1,239)
Yes
Does prehospital intravenous furosemide or nitrates improve hospital mortality or length of stay in patients with acute heart failure?
Prehospital administration of intravenous furosemide or nitrates in acute heart failure patients does not significantly improve in-hospital mortality or length of stay after adjusting for confounders.
Answers are grounded in this paper and cite their sources.
Prehospital IV furosemide showed no adjusted mortality benefit in acute HF; leaves open whether early diuretics improve outcomes and requires randomized trials.
OBJECTIVES: This study aims to evaluate the association between prehospital intravenous therapy and clinical outcomes in the patients with acute heart failure. METHODS: We conducted a prospective, multicenter observational study of consecutive AHF patients. Univariate and logistic regression analysis were performed to determine association between prehospital furosemide or nitrates administration and hospital outcome (death, length of stay). RESULTS: Data on a total of 1239 patients were processed. The mean age in the whole cohort was 71 ± 11.8 years with a gender distribution (M/F) of 634/605 patients. By prehospital treatment whole cohort was divided into 4 groups: F+ group with prehospital IV furosemide administration of 602 patients (48.6 %), F- group without prehospital IV furosemide administration of 637 patients (51.4 %), N+ group with prehospital IV nitrates administration of 110 patients (8.9 %) and N- group without IV nitrates administration of 1129 patients (91.1 %). Group of combined F+/N+ was not created. Ninety-four patients (7.6 %) died during the index hospitalization. Hospital mortality (p = 0.138) and length of stay (p = 0.101) did not differ in F+ vs F-. The patients with prehospital nitrates administration did not differ in mortality, but a shorter length of stay in univariate analysis (p = 0.03) was recorded. After adjusting for age, systolic BP and mode of referral to hospitalization, early IV furosemide usage nor nitrates showed no impact on hospital mortality and length of stay. CONCLUSIONS: Prehospital treatment with IV furosemide or nitrates in AHF patients seemed to have no major impact on hospital mortality or length of hospitalization after adjustment for several cofounders (Tab. 2, Ref. 16).
No takes yet. Share an insight, caveat, or question.
GONCALVESOVA et al. (2022) conducted an observational in Acute heart failure (n=1,239). Prehospital IV furosemide vs. No prehospital IV furosemide was evaluated on Hospital mortality (adjusted) (OR 0.67, 95% CI 0.42-1.54, p=0.089). Prehospital treatment with IV furosemide in acute heart failure patients had no significant impact on hospital mortality after adjustment for confounders.
Synapse has enriched 10 related papers. Consider them for comparative context: